Table 1 Baseline characteristics before and after PSM matched of the whole cohort.

From: Incorporating early cfEBV DNA clearance into clinical risk stratification to tailor induction chemotherapy cycles for locoregionally advanced nasopharyngeal carcinoma

 

Unmatched Cohort

PSM-matched Cohorta

Characteristicsb

2-Cycle

3-Cycle

p value

2-Cycle

3-Cycle

P valuec

Overall

857

733

 

491

491

 

Age (%)

  

0.102

  

1.00

 ≤45

387 (45.2)

362 (49.4)

 

245 (49.9)

246 (50.1)

 

 >45

470 (54.8)

371 (50.6)

246 (50.1)

245 (49.9)

Sex (%)

  

0.433

  

1.00

 Male

630 (73.5)

554 (75.6)

 

364 (74.1)

367 (74.7)

 

 Female

227 (26.5)

179 (24.4)

127 (25.9)

124 (25.3)

T Stage (%)

  

0.24

  

1.00

 T1-2

73 (8.5)

76 (10.4)

 

52 (10.6)

51 (10.4)

 

 T3-4

784 (91.5)

657 (89.6)

439 (89.4)

440 (89.6)

N Stage (%)

  

<0.001

  

0.698

 N0-1

255 (29.8)

59 (8.0)

 

63 (12.8)

58 (11.8)

 

 N2-3

602 (70.2)

674 (92.0)

428 (87.2)

433 (88.2)

Overall stage (%)

  

<0.001

  

0.589

 III

637 (74.3)

470 (64.1)

 

330 (67.2)

321 (65.4)

 

 IVA

220 (25.7)

263 (35.9)

161 (32.8)

170 (34.6)

ECOG PS (%)

  

0.006

  

0.585

 0–1

825 (96.3)

682 (93.0)

 

465 (94.7)

460 (93.7)

 

 > 1

32 (3.7)

51 (7.0)

 

26 (5.3)

31 (6.3)

 

Induction chemotherapy regimen (%)

  

<0.001

  

0.792

 GP

119 (13.9)

295 (40.2)

 

91 (18.5)

86 (17.5)

 

 TPF

363 (42.4)

213 (29.1)

180 (36.7)

196 (39.9)

 TP

213 (24.9)

115 (15.7)

120 (24.4)

110 (22.4)

 TPC

130 (15.2)

89 (12.1)

 

77 (15.7)

80 (16.3)

 

 Other or more

32 (3.7)

21 (2.9)

 

23 (4.7)

19 (3.9)

 

Pre-treatment EBV DNA level (%)

  

<0.001

  

1

 <4000 copies/mL

592 (69.1)

386 (52.7)

 

282 (57.4)

283 (57.6)

 

 ≥ 4000 copies/mL

265 (30.9)

347 (47.3)

209 (42.6)

208 (42.4)

EBV DNA level after first cycle (%)

  

0.706

  

0.898

 Undetectable

386 (45.0)

338 (46.1)

 

229 (46.6)

232 (47.3)

 

 Detectable

471 (55.0)

395 (53.9)

262 (53.4)

259 (52.7)

EBV DNA level after IC (%)

  

<0.001

  

0.733

 Undetectable

541 (63.1)

532 (72.6)

 

330 (67.2)

336 (68.4)

 

 Detectable

316 (36.9)

201 (27.4)

161 (32.8)

155 (31.6)

EBV DNA level after CCRT (%)

  

0.399

  

0.885

 Undetectable

803 (93.7)

695 (94.8)

 

465 (94.7)

467 (95.1)

 

 Detectable

54 (6.3)

38 (5.2)

 

26 (5.3)

24 (4.9)

 

Concurrent chemotherapy cycles (%)

  

<0.001

  

0.43

 2 Cycles

478 (55.8)

494 (67.4)

 

311 (63.3)

298 (60.7)

 

 3 Cycles

379 (44.2)

239 (32.6)

180 (36.7)

193 (39.3)

Adjuvant therapy (%)

  

0.002

  

0.598

 No

744 (86.8)

673 (91.8)

 

438 (89.2)

444 (90.4)

 

 Yes

113 (13.2)

60 (8.2)

 

53 (10.8)

47 (9.6)

 
  1. PSM propensity score matching, ECOG PS Eastern Cooperative Oncology Group performance status, T tumour, N node, EBV Epstein‑Barr virus, IC Induction chemotherapy, CCRT Concurrent chemoradiotherapy, GP Gemcitabine plus cisplatin, TPF Docetaxel plus cisplatin plus fluorouracil, TP Docetaxel plus cisplatin, TPC Docetaxel plus cisplatin plus capecitabine.
  2. aPSM was conducted using the 1:1 nearest-neighbour matching method to balance baseline characteristics between the 2-cycle and 3-cycle induction chemotherapy groups;
  3. bCategorical variables are presented as n (%);
  4. cp value was calculated by chi-squared test, or Fisher’s exact test, as appropriate.
Back to article page